Study guide

3.5 Infective Endocarditis, Myocarditis and Rheumatic Heart Disease

AACN Cardiac Medicine Certification CMC

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview and the CMC Test Plan

1.1 CMC Exam Format, Eligibility, Fees & Scoring 1.2 The CMC Test Plan: Four Domains and How to Study Them

2 Chapter 2: Acute Coronary Syndromes and Ischemic Heart Disease

2.1 Pathophysiology & Classification of Acute Coronary Syndromes 2.2 12-Lead ECG Localization & Cardiac Biomarker Trajectories 2.3 Acute Reperfusion Strategies & Nursing Management 2.4 Complications of Acute Myocardial Infarction 2.5 Chronic Coronary Disease, Hyperlipidemia and Lipid-Lowering Therapy

3 Chapter 3: Heart Failure, Cardiomyopathies, Pericardial and Valvular Disease

3.1 Acute Decompensated Heart Failure & Staging 3.2 Acute Cardiogenic Pulmonary Edema 3.3 Dilated, Hypertrophic, and Restrictive Cardiomyopathies 3.4 Acute Pericarditis, Cardiac Tamponade & Constrictive Pericarditis 3.5 Infective Endocarditis, Myocarditis and Rheumatic Heart Disease 3.6 Valvular Heart Disease: Stenosis & Regurgitation 3.7 Syncope: Cardiac Versus Non-Cardiac Causes and Workup

4 Chapter 4: Dysrhythmias, Conduction Disorders and Electrophysiologic Interventions

4.1 Atrial Fibrillation, Atrial Flutter & Supraventricular Tachycardias 4.2 Ventricular Arrhythmias & Cardiac Arrest Management 4.3 Atrioventricular Blocks & Intraventricular Conduction Delays 4.4 Temporary Pacing: Transcutaneous, Transvenous and Epicardial 4.5 Permanent Pacemakers, CRT and Device Troubleshooting 4.6 Implantable and Wearable Cardioverter Defibrillators 4.7 Catheter Ablation and Post-Ablation Nursing Care 4.8 Synchronized Cardioversion and Defibrillation

5 Chapter 5: Vascular Conditions and Vascular Interventions

5.1 Aortic Dissection, Aortic Aneurysms & Hypertensive Crises 5.2 Peripheral Artery Disease & Acute Limb Ischemia 5.3 Acute Venous Thrombosis, DVT and VTE Prophylaxis 5.4 Peripheral and Carotid Angiography and Interventions 5.5 Endovascular Aortic Repair: EVAR and TEVAR 5.6 Catheter-Directed Thrombolysis and Post-Intervention Vascular Complications

6 Chapter 6: Shock States and Mechanical Circulatory Support

6.1 Cardiogenic Shock Pathophysiology, Hemodynamics & Etiologies 6.2 Non-Cardiogenic Shock: Hypovolemic, Distributive and Obstructive 6.3 Multisystem Organ Dysfunction Syndrome 6.4 Intra-Aortic Balloon Pump Therapy & Waveform Optimization 6.5 Percutaneous & Surgical Mechanical Circulatory Support: Impella, VA-ECMO, LVAD

7 Chapter 7: Cardiac Procedures and Structural Heart Interventions

7.1 Diagnostic Cardiac Catheterization & Coronary Angiography Interpretation 7.2 Percutaneous Coronary Intervention: Stents, No-Reflow and Post-PCI Care 7.3 Structural Heart Interventions: TAVR, MitraClip, Pericardiocentesis 7.4 Post-Cardiac Surgery Management (>48 Hours) & Late Complications

8 Chapter 8: Cardiovascular Pharmacology

8.1 Inotropes, Vasopressors & Inodilators 8.2 Vasodilators & Antianginal Agents 8.3 Antiarrhythmic Agents: Vaughan Williams Classes I-IV 8.4 Anticoagulants, Antiplatelets, Thrombolytics & Reversal Agents 8.5 Diuretics and Decongestion Strategies 8.6 Guideline-Directed Medical Therapy for Heart Failure

9 Chapter 9: Non-Cardiovascular Conditions: Pulmonary

9.1 Acute Pulmonary Embolism 9.2 Acute Respiratory Failure and ARDS 9.3 Pleural Space Abnormalities: Pneumothorax, Effusion and Hemothorax 9.4 Pulmonary Hypertension and Right Ventricular Failure 9.5 Sleep-Disordered Breathing in Cardiac Patients

10 Chapter 10: Non-Cardiovascular Conditions: Endocrine, Renal, Hematologic, Neurologic and Behavioral

10.1 Diabetes Mellitus and Glycemic Control in Cardiac Care 10.2 Thyroid and Adrenal Disorders in the Cardiac Patient 10.3 Metabolic Syndrome and Cardiometabolic Risk 10.4 Coagulopathies: Heparin-Induced Thrombocytopenia, DIC and Bleeding Disorders 10.5 Anemia and Transfusion Management in Cardiac Patients 10.6 Acute Ischemic and Hemorrhagic Stroke in the Cardiac Patient 10.7 Acute Kidney Injury and Contrast-Associated Nephropathy 10.8 Chronic Kidney Disease and the Dialysis-Dependent Cardiac Patient 10.9 Electrolyte Imbalances and Dysrhythmia Risk 10.10 Substance Use, Withdrawal and Cardiac Effects 10.11 Non-Cardiac Chest Pain: Differential and Triage 10.12 Non-Cardiovascular Multisystem Complications in Cardiac Patients

11 Chapter 11: Monitoring and Diagnostics

11.1 Pulmonary Artery Catheterization & Hemodynamic Waveform Interpretation 11.2 Arterial Line Monitoring, Continuous Cardiac Output & ScvO2 11.3 Echocardiography, Cardiac MRI & Non-Invasive Cardiac Imaging 11.4 Stress Testing and Myocardial Perfusion Imaging 11.5 Remote Cardiovascular Monitoring and Ambulatory Rhythm Devices 11.6 Laboratory Testing in Cardiac Care 11.7 Arterial Blood Gases and Acid-Base Interpretation 11.8 Pulse Oximetry, Capnography and Chest Radiography

12 Chapter 12: Respiratory, Renal and Multisystem Therapeutic Interventions

12.1 Non-Invasive Ventilation in Cardiac Patients 12.2 Invasive Mechanical Ventilation and Heart-Lung Interactions 12.3 Renal Replacement Therapy: Hemodialysis, CRRT, SCUF and Ultrafiltration 12.4 Targeted Temperature Management After Cardiac Arrest 12.5 Palliative and End-of-Life Care in Advanced Cardiac Disease

3.5 Infective Endocarditis, Myocarditis and Rheumatic Heart Disease

Key Takeaways Explain This Topic AI

Definite infective endocarditis requires 2 major, 1 major plus 3 minor, or 5 minor Duke criteria; the 2023 Duke-ISCVID update added cardiac CT and 18F-FDG PET/CT imaging, molecular microbiology, intraoperative inspection as a major criterion, and a cardiac implantable electronic device as a minor predisposition.

Draw three blood culture sets from three separate venipuncture sites with the first and last at least one hour apart, before antibiotics; transthoracic echocardiography is only about 70% sensitive for native valves and 50% for prosthetic valves versus roughly 90-96% for transesophageal imaging.

A lengthening PR interval in aortic valve endocarditis signals perivalvular abscess invading the conduction system and warrants urgent transesophageal echocardiography and surgical consultation.

AHA prophylaxis is limited to four highest-risk conditions and uses amoxicillin 2 g orally 30-60 minutes before qualifying dental, invasive respiratory or infected-tissue procedures; the 2021 statement removed clindamycin as an alternative.

Immune checkpoint inhibitor myocarditis affects about 1% of treated patients but kills 25-50%; management is permanent drug discontinuation, high-dose IV methylprednisolone and continuous telemetry for high-grade AV block.

Last updated: August 2026

Why Inflammatory and Infectious Cardiac Disease Is Tested

Test-plan item I.A.7 covers the conditions where infection or immune activation, not atherosclerosis, is destroying the heart. These patients occupy cardiac step-down and ICU beds for weeks, and the nurse is the person who detects the complication: the new murmur, the PR interval that lengthened overnight, the sudden hemiparesis, the fever that never broke. CMC items reward recognizing the pattern early, because in endocarditis and fulminant myocarditis the window between "stable on antibiotics" and "needs the operating room today" can be a single shift.

Infective Endocarditis: Pathogenesis and Microbiology

Infection requires two things: a damaged or prosthetic endothelial surface where platelets and fibrin deposit as non-bacterial thrombotic vegetation, and bacteremia seeding that nidus. Once organisms embed in the fibrin-platelet matrix they are shielded from phagocytes and from most antibiotic penetration, which is why therapy is intravenous, bactericidal, and measured in weeks rather than days.

Setting Predominant organisms Clinical signature

Native valve, community-acquired Staphylococcus aureus (now the leading cause in the US), viridans group streptococci, Enterococcus faecalis S. aureus is acute, destructive and embolic with high mortality; viridans is subacute and follows dental sources

Healthcare-associated S. aureus including MRSA, coagulase-negative staphylococci, enterococci Vascular catheters, hemodialysis access, recent instrumentation

Early prosthetic valve endocarditis (within 12 months, especially under 2 months) Coagulase-negative staphylococci (S. epidermidis), S. aureus, gram-negative bacilli, Candida Perivalvular abscess, dehiscence, paravalvular leak; surgery frequently required

Late prosthetic valve endocarditis (beyond 12 months) Viridans streptococci, S. aureus, enterococci, coagulase-negative staphylococci Behaves like native valve disease

Cardiac implantable electronic device (CIED) infection Coagulase-negative staphylococci, S. aureus Pocket erythema or erosion, lead vegetation; complete system extraction is a Class I recommendation

Injection drug use S. aureus including MRSA, also Pseudomonas, Candida, polymicrobial Tricuspid valve predominates; septic pulmonary emboli, pleuritic pain, often no audible murmur

Culture-negative HACEK organisms (Haemophilus, Aggregatibacter, Cardiobacterium, Eikenella, Kingella), Coxiella burnetii, Bartonella, Brucella, Tropheryma whipplei Prior antibiotic exposure is the single most common reason cultures are negative

Two associations are worth memorizing because they change the workup: Streptococcus gallolyticus (formerly S. bovis) endocarditis mandates colonoscopy to look for colonic neoplasm, and Enterococcus faecalis points toward a genitourinary or gastrointestinal source, classically an older man after a urologic procedure.

Diagnosis: Duke Criteria, Cultures and Echocardiography

The modified Duke criteria remain the framework, updated in 2023 as the Duke-ISCVID criteria to add molecular microbiology, advanced imaging and intraoperative inspection.

Major criteria Minor criteria

Microbiologic : a typical organism from two separate blood cultures (viridans streptococci, S. gallolyticus, HACEK, S. aureus, or community-acquired enterococci without a primary focus); or persistently positive cultures drawn more than 12 hours apart; or a single positive culture for Coxiella burnetii or phase I IgG titer above 1:800 Predisposition : prior endocarditis, prosthetic valve or valve repair material, congenital heart disease, moderate-to-severe valvular lesion, hypertrophic obstructive cardiomyopathy, injection drug use, and (added in 2023) a cardiac implantable electronic device

Imaging : echocardiographic vegetation, abscess, pseudoaneurysm or intracardiac fistula, new partial dehiscence of a prosthetic valve, or new valvular regurgitation. The 2023 update adds cardiac CT evidence of paravalvular lesions and abnormal 18F-FDG PET/CT uptake around a prosthetic valve, CIED lead or vascular graft Fever above 38.0 degrees C

Surgical (new in 2023): intraoperative inspection confirming endocarditis Vascular phenomena : arterial emboli, septic pulmonary infarcts, mycotic aneurysm, intracranial or conjunctival hemorrhage, Janeway lesions, splenic abscess

  • Immunologic phenomena : glomerulonephritis, Osler nodes, Roth spots, positive rheumatoid factor
  • Microbiologic evidence not meeting a major criterion

Definite endocarditis requires 2 major, or 1 major plus 3 minor, or 5 minor criteria (or pathologic confirmation). Possible endocarditis requires 1 major plus 1 minor, or 3 minor criteria.

The classic peripheral stigmata appear in fewer than a quarter of modern cases, mostly in subacute streptococcal disease, but they are exam favorites: Osler nodes are painful and sit on the finger and toe pads (Osler equals ouch, immune-complex mediated); Janeway lesions are painless macules on palms and soles (septic microemboli); Roth spots are retinal hemorrhages with pale centers; splinter hemorrhages are linear nailbed streaks. Add conjunctival petechiae, palatal petechiae and splenomegaly.